(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Trial details
- Registry ID
- NCT05607004
- Phase
- Phase 2
The FDA approved goserelin (Zoladex) on 29 Dec 1989.
Drug identity checked against registry records
Also recorded as Zoladex
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast CancerNCT05607004 | ATOS | Phase 2 | Active not recruiting | 2026-11Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1989-12-29Day | goserelin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA019726", "applicant_as_listed_by_fda": "TERSERA", "brand_names": ["ZOLADEX"], "active_ingredients": ["GOSERELIN ACETATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19891229", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |